209eP Real-world experience with trastuzumab deruxtecan in metastatic ERBB2-altered non-small cell lung cancer

second-line therapy in patients after progression of first-line ICIs therapy does not show significant differences due to the type of treatment strategies.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106516
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

209eP Real-world experience with trastuzumab deruxtecan in metastatic ERBB2-altered non-small cell lung cancer

P. Sastry, S. Advani, P. Ganatra, S. Ranjan et al.
ESMO Open
Lung Cancer Treatments and Mutations
article

209eP Real-world experience with trastuzumab deruxtecan in metastatic ERBB2-altered non-small cell lung cancer

P. Sastry, S. Advani, P. Ganatra, S. Ranjan, S. Jiwatani
article en

Abstract

second-line therapy in patients after progression of first-line ICIs therapy does not show significant differences due to the type of treatment strategies.

ESMO OpenVol. 11
Bombay Hospital (IN)
Good health and well-being
Openalex Percentile: Top 20%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.